Jan 08, 2024

Servier Will Apply Aitia’s Gemini Digital Twins to Parkinson’s Drug

Spotlight on our joint effort with Servier, strengthening our partnership by entering a new collaboration focused on neuroscience. The aim of this cooperation is to leverage Aitia’s Gemini Digital Twins to identify patients most likely to respond positively to Servier’s Leucine-Rich-Repeat-Kinase 2 inhibitor (LRRK2i) in development treatment for Parkinson’s disease.

Read the full article on our latest collaboration featured in Pharmaphorum for a deeper insight into the future of neuroscience innovation. Full article here.